Skip to main content

Table 1 Demographic and baseline characteristics of safety population by treatment group

From: A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

Characteristic

Placebo

Desvenlafaxine

Desvenlafaxine

(n = 223)

10 mg/d (n = 226)

50 mg/d (n = 224)

Age, y

42 ± 13

41 ± 14

43 ± 14

Age group, n (%)

   

  18-64 y

215 (96)

212 (94)

213 (95)

  >64 y

8 (4)

14 (6)

11 (5)

Female, n (%)

139 (62)

135 (60)

135 (60)

Race, n (%)

   

  White

176 (79)

199 (88)

177 (79)

  Black

38 (17)

20 (9)

37 (17)

  Asian

4 (2)

3 (1)

2 (1)

  Other

5 (2)

4 (2)

8 (4)

Weight, kg

87 ± 24

88 ± 27

91 ± 26

Body mass index, kg/m 2

30 ± 7

31 ± 9

32 ± 8

Baseline HAM-D 17 score

23 ± 3

23 ± 2

23 ± 3

Duration of current depressive episode, mo

34 ± 81

26 ± 48

31 ± 76

  1. Data are presented as mean ± standard deviation unless otherwise indicated.
  2. d, day; HAM-D17, 17-item Hamilton Rating Scale for Depression; ITT, intent-to-treat; kg, kilogram; m, meter; mo, months; y, years.